<b>Conclusions:</b> Our results uncover a novel mechanism by which inhibiting DYRK1B enhances the anti-HGSOC efficacy of Niraparib and may offer a promising treatment strategy to improve the maintenance therapy in both HRD and HRP ovarian cancer patients. This evidence concerns the gene DYRK1B and hypoparathyroidism-retardation-dysmorphism syndrome.